

**Arterial events, venous thromboembolism,
thrombocytopenia, and bleeding after
Oxford-AstraZeneca COVID-19 vaccination:
A Danish-Norwegian cohort study**

SUPPLEMENTARY MATERIAL

Appendix. ICD-10 Diagnosis codes used in the study.

Arterial vascular events		
Cardiac events	I21	Acute myocardial infarction (AMI)
	I20, 23-25	Ischaemic heart disease without AMI
Cerebrovascular events	I60	Subarachnoid haemorrhage (SAH)
	I61	Intracerebral haemorrhage (ICH)
	I62	Unspecified nontraumatic intracranial haemorrhage
	I63	Cerebral infarction
	I636	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
	I64	Stroke, unspecified
	I65-I66	Occlusion/stenosis of precerebral or cerebral arteries, not resulting in cerebral infarction
Other necrotising vasculitis	G450-G453	Transient cerebral ischaemic attack
	M31	Other necrotising vasculitis
	M310	Angiitis hypersensitiva
	M311	Microangiopathia thrombotica
	M318	Other necrotising vasculitis
Venous thromboembolism		
Pulmonary embolism	I26	Pulmonary embolism (PE)
Lower limb venous thrombosis	I801	Thrombophlebitis of femoral vein
	I802	Deep thrombophlebitis of veins in leg
	I803	Unspecified deep thrombophlebitis in lower limb
Splanchnic thrombosis	I81	Portal thrombosis
	I820	Budd-Chiari syndrome
	I823	Embolism and thrombosis in renal vein
Cerebral venous thrombosis	I676	Nonpyogenic cerebral venous thrombosis
Other venous thrombosis	I828	Embolism and thrombosis in other specified veins
	I829	Embolism and thrombosis in non-specified veins
	I822	Embolism and thrombosis of caval vein
Thrombocytopenia and coagulative disorders		
Coagulative disorders	D65+68	Coagulation disorders, purpura
	D65	Disseminated intravascular coagulation (DIC)
Thrombocytopenia	D693-D696	Thrombocytopenia
	D693	Idiopathic thrombocytopenic purpura
	D694	Other primary thrombocytopenia
	D695	Secondary thrombocytopenia
	D696	Thrombocytopenia unspecified
Bleeding events		
Haemolytic anaemias	D55-57+59	Haemolytic anaemias
	D593	Haemolytic uremic syndrome
	D595	Paroxysmal nocturnal hemoglobinuria
Bleedings	D62	Anemias from bleeding
	D629	Anaemia from bleeding, unspecified
	K922 ^a	Intestinal bleeding
	R04	Bleeding from respiratory tract
	R31	Haematuria
	R58	Bleeding, not specified

^a Not available in the Norwegian data source.

Supplementary Table 1

General population incidence rates (using a more recent general population cohort 1 January 2020 to 15 March 2021), observed and expected counts of events, standardized morbidity differences (/100,000 vaccinations), and standardised morbidity ratios of arterial events and venous thromboembolism within 28 days of vaccination in a cohort of 18-65 year old Danish and Norwegian persons (n=281,264) receiving their first administration of the Oxford-AstraZeneca COVID-19 vaccine.

Outcome	Incidence rate ^a		Expected	Standardised morbidity difference ^c	Standardised morbidity ratio	
	DK / NO	Observed ^b		/100,000 (95% CI)	(95% CI)	
ARTERIAL EVENTS	4.44 / 4.64	83	83	0.1 (-6.2 to 7.5)	1.00 (0.80 to 1.24)	■
Cardiac events	2.82 / 3.49	52	55	-1.0 (-5.8 to 5.1)	0.95 (0.71 to 1.25)	■
Acute myocardial infarction (AMI)	1.02 / 1.16	20	18	0.8 (-2.1 to 4.8)	1.12 (0.68 to 1.73)	■
Ischaemic heart disease without AMI	2.46 / 3.29	46	49	-1.2 (-5.8 to 4.5)	0.93 (0.68 to 1.24)	■
Cerebrovascular events	1.64 / 1.2	27	28	-0.4 (-3.8 to 4.1)	0.96 (0.63 to 1.39)	■
Cerebral infarction	1.13 / 0.74	16	18	-0.7 (-3.2 to 3.0)	0.90 (0.51 to 1.46)	■
Intracerebral haemorrhage (ICH)	0.21 / 0.16	8	4	1.6 (-0.1 to 4.5)	2.17 (0.94 to 4.27)	■
Occlusion and stenosis not resulting in cerebral infarction ^d	0.05 / 0.21	n<5	3	NR	NR	
Stroke, unspecified	0.24 / 0.05	0	3	-1.1 (-1.1 to 0.3)	0.00 (0.00 to 1.26)	
Subarachnoid haemorrhage (SAH)	0.12 / 0.09	n<5	3	NR	NR	
Transient cerebral ischemic attack	0.08 / 0.10	0	2	-0.7 (-0.7 to 0.7)	0.00 (0.00 to 2.01)	
Other arterial events ^e	0.10 / 0.10	n<5	2	NR	NR	
VENOUS THROMBOEMBOLISM	1.55 / 1.3	59	30	10.9 (5.6 to 17.2)	1.99 (1.51 to 2.57)	■
Cerebral venous thrombosis	0.01 / 0.01	7	0	2.5 (0.9 to 5.2)	20.10 (8.08 to 41.42)	■
Pulmonary embolism (PE)	0.6 / 0.63	21	12	3.2 (0.2 to 7.3)	1.69 (1.05 to 2.59)	■
Lower limb venous thrombosis	0.78 / 0.45	22	13	3.4 (0.3 to 7.6)	1.71 (1.07 to 2.58)	■
Deep thrombophlebitis of veins in legs	0.29 / 0.36	10	7	1.3 (-0.7 to 4.4)	1.52 (0.73 to 2.79)	■
Unspecified deep thrombophlebitis in lower limb	0.53 / 0.04	12	6	2.2 (0.0 to 5.5)	1.95 (1.01 to 3.40)	■
Splanchnic thrombosis	0.05 / 0.06	n<5	1	NR	NR	
Other venous thrombosis ^f	0.29 / 0.36	12	7	1.9 (-0.2 to 5.2)	1.75 (0.91 to 3.06)	■

Abbreviations:

CI: confidence interval; DK, Denmark; NO, Norway; NR, Not reported due to privacy regulations.

^a Incidence rate per 1,000 person years in the general population.

^b Observed events are not mutually exclusive, i.e. one patient can contribute to two different third-level outcomes. However, two different third-level outcomes would only count once towards a common second-level outcome and similarly only once in a first-level outcome.

^c Standardised morbidity differences are estimated as excess events per 100,000 vaccine recipients followed for 28 days each by comparing observed to expected events, the latter based on the incidence rates in the general population.

^d Full name: Occlusion and stenosis of precerebral or cerebral arteries, not resulting in cerebral infarction.

^e Including angitis hypersensitiva, angitis hypersensitiva with Schönlein-Henochs purpura, Buerger's syndrome, Goodpasture syndrome, microangiopathy thrombotica, other necrotising vasculitis, and thrombotic thrombocytopenic purpura.

^f Including embolism and thrombosis in non-specified veins, embolism and thrombosis in other specified veins, and embolism and thrombosis of caval vein

Supplementary Table 2

General population incidence rates (using a more recent general population cohort 1 January 2020 to 15 March 2021), observed and expected counts of events, standardized morbidity differences (/100,000 vaccinations), and standardised morbidity ratios of thrombocytopenia and coagulative disorders and bleeding events within 28 days of vaccination in a cohort of 18-65 year old Danish and Norwegian persons (n=281,264) receiving their first administration of the Oxford-AstraZeneca COVID-19 vaccine.

Outcome	Incidence rate ^a		Expected	Standardised morbidity difference ^c /100,000 (95% CI)	Standardised morbidity ratio (95% CI)	SMR
	DK / NO	Observed ^b				
THROMBOCYTOPENIA AND COAGULATIVE DISORDERS	0.49 / 0.75	24	14	3.5 (0.3 to 7.9)	1.66 (1.06 to 2.47)	■
Thrombocytopenia	0.11 / 0.38	17	5	4.4 (1.7 to 8.1)	3.24 (1.89 to 5.19)	■
Idiopathic thrombocytopenic purpura	0.04 / 0.06	n<5	1	NR	NR	
Other primary thrombocytopenia	0.00 / 0.01	0	0	-0.1 (-0.1 to 1.3)	0.00 (0.00 to 24.67)	
Secondary thrombocytopenia	0.01 / 0.17	NR	2	NR	NR	
Thrombocytopenia unspecified	0.07 / 0.20	11	3	3.0 (1.0 to 6.2)	3.77 (1.88 to 6.75)	■
Coagulative disorders	0.39 / 0.39	7	9	-0.9 (-2.5 to 1.8)	0.74 (0.30 to 1.53)	■
Coagulative disorders, purpura	0.39 / 0.39	7	9	-0.9 (-2.5 to 1.8)	0.74 (0.30 to 1.53)	■
Disseminated intravascular coagulation (DIC)	0.01 / 0.02	0	0	-0.1 (-0.1 to 1.3)	0.00 (0.00 to 20.87)	
BLEEDING EVENTS	2.47 / 2.62	74	52	8.1 (2.2 to 15.1)	1.42 (1.11 to 1.78)	■
Bleedings	2.38 / 2.55	74	50	8.8 (2.9 to 15.8)	1.47 (1.15 to 1.84)	■
Anemia from bleeding	0.08 / 0.58	n<5	8	NR	NR	
Bleeding from respiratory tract	0.80 / 0.75	35	15	7.5 (3.5 to 12.5)	2.36 (1.65 to 3.29)	■
Bleeding, not specified	0.19 / 0.05	8	3	1.8 (0.2 to 4.7)	2.64 (1.14 to 5.19)	■
Hematuria	1.22 / 1.22	25	24	0.2 (-3.1 to 4.6)	1.02 (0.66 to 1.51)	■
Intestinal bleeding	0.12 / - ^d	n<5	1	NR	NR	
Hemolytic anemias ^e	0.09 / 0.08	0	2	-0.8 (-0.8 to 0.6)	0.00 (0.00 to 1.81)	

Abbreviations:

CI: confidence interval; DK, Denmark; NO, Norway; NR, Not reported due to privacy regulations.

^a Incidence rate per 1,000 person years in the general population.

^b Observed events are not mutually exclusive, i.e. one patient can contribute to two different third-level outcomes. However, two different third-level outcomes would only count once towards a common second-level outcome and similarly only once in a first-level outcome.

^c Standardised morbidity differences are estimated as excess events per 100,000 vaccine recipients followed for 28 days each by comparing observed to expected events, the latter based on the incidence rates in the general population.

^d Not available in the Norwegian data source.

^e Including hemolytic anemia, hemolytic uremic syndrome, and paroxysmal nocturnal haemoglobinuria.

Supplementary Table 3

Proportion of individuals in the Danish Oxford-AstraZeneca COVID-19 vaccine cohort and in the Danish general population who redeemed a prescription for systemic hormone therapy* during the 365 days preceding vaccination or 1 January of the given year.

Age category	Oxford-AstraZeneca, n/N (%)	2016, n/N (%)	2017, n/N (%)	2018, n/N (%)	2020-2021, n/N (%)
Total	17242/119119 (14.5)	369448/1709814 (21.6)	337718/1692934 (19.9)	302986/1679309 (18.0)	288990/1740062 (16.6)
18-24	6487/111132 (58.3)	136759/241822 (56.6)	138740/238417 (58.2)	134049/235176 (57.0)	128907/243959 (52.8)
25-29	4232/10452 (40.5)	84007/171028 (49.1)	72621/166616 (43.6)	61719/163852 (37.7)	65103/187820 (34.7)
30-34	2086/9531 (21.9)	48073/154673 (31.1)	40604/152234 (26.7)	34479/150553 (22.9)	33595/170612 (19.7)
35-39	1256/11188 (11.2)	34713/164209 (21.1)	29630/162923 (18.2)	25103/161905 (15.5)	20530/159688 (12.9)
40-44	986/13916 (7.1)	27628/187766 (14.7)	23396/186816 (12.5)	19612/186049 (10.5)	15232/180057 (8.5)
45-49	753/15976 (4.7)	18842/192697 (9.8)	15841/191886 (8.3)	13293/191166 (7.0)	11228/194528 (5.8)
50-54	712/16045 (4.4)	11363/208841 (5.4)	9663/207929 (4.6)	8255/207043 (4.0)	7699/203677 (3.8)
55-59	511/17324 (2.9)	4790/182785 (2.6)	4287/181807 (2.4)	3790/180829 (2.1)	4201/193021 (2.2)
60-65	219/13555 (1.6)	3273/205993 (1.6)	2936/204306 (1.4)	2686/202736 (1.3)	2495/206700 (1.2)

* Systemic hormone therapy was defined as the following ATC codes, restricted to systemic administration: G03AA, G03AB, G02BB01, G03HB01 (oral contraceptives, combination therapy) and G03CA

Supplementary Table 4

General population incidence rates for arterial events and venous thromboembolism in Denmark, stratified by calendar year.

Outcome	2016			2017			2018			2016-2018			2020 - March 2021		
	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a
ARTERIAL EVENTS	16314	3408	4.79	15159	3349	4.53	14017	3306	4.24	45490	10063	4.52	18381	4136	4.44
Cardiac events	10952	3416	3.21	9837	3362	2.93	8816	3323	2.65	29605	10102	2.93	11711	4148	2.82
Acute myocardial infarction (AMI)	3498	3431	1.02	3504	3383	1.04	3538	3350	1.06	10540	10164	1.04	4229	4164	1.02
Ischaemic heart disease without AMI	9850	3418	2.88	8724	3365	2.59	7561	3327	2.27	26135	10111	2.58	10190	4151	2.46
Cerebrovascular events	5407	3428	1.58	5557	3379	1.64	5479	3344	1.64	16443	10151	1.62	6803	4160	1.64
Cerebral infarction	3272	3431	0.95	3486	3384	1.03	3684	3350	1.10	10442	10166	1.03	4694	4164	1.13
Intracerebral haemorrhage (ICH)	698	3435	0.20	690	3390	0.20	689	3360	0.21	2077	10185	0.20	860	4170	0.21
Occlusion and stenosis not resulting in cerebral infarction ^b	282	3436	0.08	258	3391	0.08	208	3361	0.06	748	10188	0.07	226	4171	0.05
Stroke, unspecified	1460	3434	0.43	1440	3388	0.42	1184	3357	0.35	4084	10179	0.40	1010	4170	0.24
Subarachnoid haemorrhage (SAH)	538	3435	0.16	477	3391	0.14	400	3360	0.12	1415	10186	0.14	489	4170	0.12
Transient cerebral ischemic attack	223	3436	0.06	226	3391	0.07	240	3361	0.07	689	10188	0.07	314	4171	0.08
Other arterial events^c	411	3435	0.12	382	3391	0.11	355	3360	0.11	1148	10186	0.11	411	4170	0.10
VENOUS THROMBOEMBOLISM	5005	3429	1.46	5841	3380	1.73	5208	3344	1.56	16054	10152	1.58	6456	4159	1.55
Cerebral venous thrombosis	55	3436	0.02	74	3392	0.02	54	3361	0.02	183	10189	0.02	62	4171	0.01
Pulmonary embolism	1814	3433	0.53	2122	3388	0.63	1826	3356	0.54	5762	10177	0.57	2501	4167	0.60
Lower limb venous thrombosis	2948	3432	0.86	3466	3385	1.02	3124	3351	0.93	9538	10167	0.94	3266	4164	0.78
Deep thrombophlebitis of veins in legs	1120	3435	0.33	1206	3389	0.36	1249	3358	0.37	3575	10182	0.35	1219	4169	0.29
Unspecified deep thrombophlebitis in lower limb	2091	3433	0.61	2574	3387	0.76	2069	3354	0.62	6734	10174	0.66	2202	4167	0.53
Splanchnic thrombosis	147	3436	0.04	160	3392	0.05	122	3361	0.04	429	10188	0.04	207	4171	0.05
Other venous thrombosis^d	672	3435	0.20	832	3390	0.25	747	3359	0.22	2251	10184	0.22	1189	4169	0.29

Abbreviations:

PY: person years; IR: Incidence rate

^a Incidence rate per 1,000 person years.

^b Full name: Occlusion and stenosis of precerebral or cerebral arteries, not resulting in cerebral infarction.

^c Including angitis hypersensitiva, angitis hypersensitiva with Schönlein-Henochs purpura, Buerger's syndrome, Goodpasture syndrome, microangiopathia thrombotica, other necrotising vasculitis, and thrombotic thrombocytopenic purpura.

^d Including embolism and thrombosis in non-specified veins, embolism and thrombosis in other specified veins, and embolism and thrombosis of caval vein

Supplementary Table 5

General population incidence rates for thrombocytopenia and coagulative disorders and bleeding events in Denmark, stratified by calendar year

Outcome	2016			2017			2018			2016-2018			2020 - March 2021		
	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a
THROMBOCYTOPENIA AND COAGULATIVE DISORDERS	2267	3433	0.66	2187	3386	0.65	1641	3354	0.49	6095	10173	0.60	2056	4166	0.49
Thrombocytopenias	629	3435	0.18	451	3391	0.13	430	3360	0.13	1510	10186	0.15	454	4170	0.11
Idiopathic thrombocytopenic purpura	287	3436	0.08	235	3391	0.07	157	3361	0.05	679	10187	0.07	157	4170	0.04
Other primary thrombocytopenia	16	3436	0.00	5	3392	0.00	7	3361	0.00	28	10189	0.00	14	4171	0.00
Secondary thrombocytopenia	45	3436	0.01	27	3392	0.01	37	3361	0.01	109	10189	0.01	30	4171	0.01
Thrombocytopenia unspecified	344	3436	0.10	253	3391	0.07	290	3361	0.09	887	10187	0.09	298	4171	0.07
Coagulative disorders	1654	3434	0.48	1751	3388	0.52	1223	3356	0.36	4628	10177	0.45	1615	4167	0.39
Coagulative disorders, purpura	1654	3434	0.48	1751	3388	0.52	1223	3356	0.36	4628	10177	0.45	1615	4167	0.39
Disseminated intravascular coagulation (DIC)	50	3436	0.01	29	3392	0.01	26	3361	0.01	105	10189	0.01	17	4171	0.00
BLEEDING EVENTS	9760	3420	2.85	9182	3367	2.73	8902	3328	2.68	27844	10114	2.75	10240	4154	2.47
Bleedings	9413	3420	2.75	8875	3367	2.64	8682	3329	2.61	26970	10117	2.67	9885	4155	2.38
Anemia from bleeding	403	3436	0.12	356	3391	0.10	321	3360	0.10	1080	10187	0.11	343	4171	0.08
Bleeding from respiratory tract	2832	3432	0.83	2851	3385	0.84	2941	3352	0.88	8624	10169	0.85	3316	4166	0.80
Bleeding, not specified	446	3436	0.13	502	3391	0.15	581	3360	0.17	1529	10186	0.15	777	4170	0.19
Hematuria	5165	3426	1.51	4790	3377	1.42	4563	3342	1.37	14518	10146	1.43	5074	4163	1.22
Intestinal bleeding	731	3435	0.21	575	3390	0.17	504	3360	0.15	1810	10185	0.18	513	4171	0.12
Hemolytic anemias^b	366	3436	0.11	321	3391	0.09	246	3360	0.07	933	10187	0.09	383	4170	0.09

Abbreviations:

PY: person years; IR: Incidence rate

^a Incidence rate per 1,000 person years.

^b Including hemolytic anemia, hemolytic uremic syndrome, and paroxysmal nocturnal haemoglobinuria.

Supplementary Table 6

General population incidence rates for arterial events and venous thromboembolism in Norway, stratified by calendar year.

Outcome	2018			2019			2018-2019			2020 - March 2021		
	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a
ARTERIAL VASCULAR EVENTS	15786	3315	4.76	15263	3276	4.66	31049	6591	4.71	18457	3977	4.64
Cardiac events	11972	3322	3.60	11552	3286	3.52	23524	6608	3.56	13901	3986	3.49
Acute myocardial infarction (AMI)	3882	3339	1.16	4180	3311	1.26	8062	6650	1.21	4654	4007	1.16
Ischaemic heart disease without AMI	11289	3324	3.40	10833	3288	3.29	22122	6612	3.35	13137	3987	3.29
Cerebrovascular events	3970	3339	1.19	4048	3310	1.22	8018	6649	1.21	4805	4007	1.20
Cerebral infarction	2395	3342	0.72	2596	3314	0.78	4991	6656	0.75	2974	4010	0.74
Intracerebral haemorrhage (ICH)	462	3345	0.14	502	3319	0.15	964	6664	0.14	642	4014	0.16
Occlusion and stenosis not resulting in cerebral infarction ^b	742	3344	0.22	659	3318	0.20	1401	6662	0.21	833	4014	0.21
Stroke unspecified	236	3345	0.07	189	3320	0.06	425	6665	0.06	181	4015	0.05
Subarachnoid haemorrhage (SAH)	303	3345	0.09	323	3320	0.10	626	6664	0.09	350	4015	0.09
Transient cerebral ischemic attack	305	3345	0.09	325	3319	0.10	630	6664	0.09	395	4014	0.10
Other arterial events	369	3344	0.11	319	3319	0.10	688	6663	0.10	393	4013	0.10
VENOUS THROMBOEMBOLISM	4125	3339	1.24	4233	3310	1.28	8358	6649	1.26	5203	4006	1.30
Cerebral venous thrombosis	35	3345	0.01	30	3320	0.01	65	6665	0.01	55	4015	0.01
Pulmonary embolism	1851	3342	0.55	1968	3316	0.59	3819	6658	0.57	2515	4011	0.63
Lower limb thrombosis	1552	3343	0.46	1638	3316	0.49	3190	6659	0.48	1809	4012	0.45
Deep thrombophlebitis of veins in legs	1218	3343	0.36	1312	3317	0.40	2530	6660	0.38	1446	4013	0.36
Unspecified deep thrombophlebitis in lower limb	161	3345	0.05	189	3320	0.06	350	6665	0.05	171	4015	0.04
Splancnic thrombosis	198	3345	0.06	201	3320	0.06	399	6665	0.06	240	4015	0.06
Other venous thrombosis^d	1240	3343	0.37	1154	3317	0.35	2394	6661	0.36	1442	4013	0.36

Abbreviations:

PY: person years; IR: Incidence rate

^a Incidence rate per 1,000 person years.

^b Full name: Occlusion and stenosis of precerebral or cerebral arteries, not resulting in cerebral infarction.

^c Including angitis hypersensitiva, angitis hypersensitiva with Schönlein-Henochs purpura, Buerger's syndrome, Goodpasture syndrome, microangiopathia thrombotica, other necrotising vasculitis, and thrombotic thrombocytopenic purpura.

^d Including embolism and thrombosis in non-specified veins, embolism and thrombosis in other specified veins, and embolism and thrombosis of caval vein

Supplementary Table 7

General population incidence rates for thrombocytopenia and coagulative disorders and bleeding events in Norway, stratified by calendar year

Outcome	2018			2019			2018-2019			2020 - March 2021		
	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a	Events	1000 PY	IR ^a
THROMBOCYTOPENIA AND COAGULATIVE DISORDERS	2521	3341	0.75	2445	3314	0.74	4966	6655	0.75	3011	4010	0.75
Thrombocytopenia	1290	3343	0.39	1228	3317	0.37	2518	6661	0.38	1513	4013	0.38
Idiopathic thrombocytopenic purpura	218	3345	0.07	181	3320	0.05	399	6664	0.06	233	4014	0.06
Other primary thrombocytopenia	18	3345	0.01	27	3320	0.01	45	6665	0.01	34	4015	0.01
Secondary thrombocytopenia	585	3344	0.17	583	3319	0.18	1168	6664	0.18	696	4014	0.17
Thrombocytopenia unspecified	655	3344	0.20	674	3319	0.20	1329	6663	0.20	785	4014	0.20
Coagulative disorders	1285	3343	0.38	1258	3317	0.38	2543	6660	0.38	1556	4012	0.39
Coagulative disorders, purpura	1285	3343	0.38	1258	3317	0.38	2543	6660	0.38	1556	4012	0.39
Disseminated intravascular coagulation (DIC)	61	3345	0.02	59	3320	0.02	120	6665	0.02	63	4015	0.02
BLEEDING EVENTS	10286	3329	3.09	9857	3295	2.99	20143	6624	3.04	10451	3996	2.62
Bleedings	10020	3330	3.01	9597	3295	2.91	19617	6625	2.96	10175	3997	2.55
Anemia from bleeding	2037	3342	0.61	1988	3315	0.60	4025	6658	0.60	2309	4012	0.58
Bleeding from respiratory tract	2978	3341	0.89	2801	3313	0.85	5779	6654	0.87	3008	4010	0.75
Bleeding, not specified	152	3345	0.05	155	3320	0.05	307	6665	0.05	187	4015	0.05
Hematuria	5055	3337	1.51	4916	3307	1.49	9971	6645	1.50	4890	4006	1.22
Hemolytic anemias^b	288	3345	0.09	290	3319	0.09	578	6664	0.09	308	4014	0.08

Abbreviations:

PY: person years; IR: Incidence rate

^a Incidence rate per 1,000 person years.

^b Including hemolytic anemia, hemolytic uremic syndrome, and paroxysmatic nocturnal haemoglobinuria.